{"id":21835,"date":"2022-07-13T05:00:00","date_gmt":"2022-07-12T21:00:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=21835"},"modified":"2022-07-13T06:22:51","modified_gmt":"2022-07-12T22:22:51","slug":"jama%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e6%97%a2%e5%be%80%e6%8e%a5%e7%a7%8d%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%be%89%e7%91%9emrna%e7%96%ab%e8%8b%97%e4%b8%8e%e5%a5%a5%e5%af%86%e5%85%8b","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=21835","title":{"rendered":"[JAMA\u53d1\u8868\u8bba\u6587]\uff1a\u65e2\u5f80\u63a5\u79cd\u65b0\u51a0\u75c5\u6bd2\u8f89\u745emRNA\u75ab\u82d7\u4e0e\u5965\u5bc6\u514b\u620e\u6d41\u884c\u671f\u95f4\u513f\u7ae5\u548c\u9752\u5c11\u5e74\u6709\u75c7\u72b6\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3\u7684\u76f8\u5173\u6027"},"content":{"rendered":"\n

Original Investigation May 13, 2022<\/p>\n\n\n\n

Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance<\/h1>\n\n\n\n

Katherine E.\u00a0Fleming-Dutra,\u00a0Amadea\u00a0Britton,\u00a0Nong\u00a0Shang,\u00a0et al<\/h3>\n\n\n\n

JAMA.\u00a0<\/em>Published online May 13, 2022. doi:10.1001\/jama.2022.7493<\/h3>\n\n\n\n

Key Points<\/p>\n\n\n\n

Question<\/strong>  Does the estimated effectiveness of 2 doses of the BNT162b2 COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron variant infection (based on the odds ratio for the association of prior vaccination and infection) wane rapidly among children and adolescents, as has been observed for adults?<\/p>\n\n\n\n

Findings<\/strong>  In a test-negative, case-control study conducted from December 2021 to February 2022 during Omicron variant predominance that included 121\u202f952 tests from sites across the US, estimated vaccine effectiveness against symptomatic infection for children 5 to 11 years of age was 60.1% 2 to 4 weeks after dose 2 and 28.9% during month 2 after dose 2. Among adolescents 12 to 15 years of age, estimated vaccine effectiveness was 59.5% 2 to 4 weeks after dose 2 and 16.6% during month 2; estimated booster dose effectiveness in adolescents 2 to 6.5 weeks after the booster was 71.1%.<\/p>\n\n\n\n

Meaning<\/strong>  Among children and adolescents, estimated vaccine effectiveness for 2 doses of BNT162b2 against symptomatic infection decreased rapidly, and among adolescents increased after a booster dose.<\/a>Abstract<\/p>\n\n\n\n

Importance<\/strong>  Efficacy of 2 doses of the BNT162b2 COVID-19 vaccine (Pfizer-BioNTech) against COVID-19 was high in pediatric trials conducted before the SARS-CoV-2 Omicron variant emerged. Among adults, estimated vaccine effectiveness (VE) of 2 BNT162b2 doses against symptomatic Omicron infection was reduced compared with prior variants, waned rapidly, and increased with a booster.<\/p>\n\n\n\n

Objective<\/strong>  To evaluate the association of symptomatic infection with prior vaccination with BNT162b2 to estimate VE among children and adolescents during Omicron variant predominance.<\/p>\n\n\n\n

Design, Setting, and Participants<\/strong>  A test-negative, case-control analysis was conducted using data from 6897 pharmacy-based, drive-through SARS-CoV-2 testing sites across the US from a single pharmacy chain in the Increasing Community Access to Testing platform. This analysis included 74\u202f208 tests from children 5 to 11 years of age and 47\u202f744 tests from adolescents 12 to 15 years of age with COVID-19\u2013like illness who underwent SARS-CoV-2 nucleic acid amplification testing from December 26, 2021, to February 21, 2022.<\/p>\n\n\n\n

Exposures<\/strong>  Two BNT162b2 doses 2 weeks or more before SARS-CoV-2 testing vs no vaccination for children; 2 or 3 doses 2 weeks or more before testing vs no vaccination for adolescents (who are recommended to receive a booster dose).<\/p>\n\n\n\n

Main Outcomes and Measures<\/strong>  Symptomatic infection. The adjusted odds ratio (OR) for the association of prior vaccination and symptomatic SARS-CoV-2 infection was used to estimate VE: VE\u2009=\u2009(1\u2009\u2212\u2009OR)\u2009\u00d7\u2009100%.<\/p>\n\n\n\n

Results<\/strong>  A total of 30\u202f999 test-positive cases and 43\u202f209 test-negative controls were included from children 5 to 11 years of age, as well as 22\u202f273 test-positive cases and 25\u202f471 test-negative controls from adolescents 12 to 15 years of age. The median age among those with included tests was 10 years (IQR, 7-13); 61\u202f189 (50.2%) were female, 75\u202f758 (70.1%) were White, and 29\u202f034 (25.7%) were Hispanic\/Latino. At 2 to 4 weeks after dose 2, among children, the adjusted OR was 0.40 (95% CI, 0.35-0.45; estimated VE, 60.1% [95% CI, 54.7%-64.8%]) and among adolescents, the OR was 0.40 (95% CI, 0.29-0.56; estimated VE, 59.5% [95% CI, 44.3%-70.6%]). During month 2 after dose 2, among children, the OR was 0.71 (95% CI, 0.67-0.76; estimated VE, 28.9% [95% CI, 24.5%-33.1%]) and among adolescents, the OR was 0.83 (95% CI, 0.76-0.92; estimated VE, 16.6% [95% CI, 8.1%-24.3%]). Among adolescents, the booster dose OR 2 to 6.5 weeks after the dose was 0.29 (95% CI, 0.24-0.35; estimated VE, 71.1% [95% CI, 65.5%-75.7%]).<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions and Relevance<\/strong>  Among children and adolescents, estimated VE for 2 doses of BNT162b2 against symptomatic infection was modest and decreased rapidly. Among adolescents, the estimated effectiveness increased after a booster dose.<\/p>\n","protected":false},"excerpt":{"rendered":"

Original Investigation May 13, 2022 Asso […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21835"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21835"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21835\/revisions"}],"predecessor-version":[{"id":21836,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21835\/revisions\/21836"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}